Study, Jul/18:Patterns of benzo use - primary care adults with anxiety disorders

https://www.ncbi.nlm.nih.gov/pubmed/29998202 

2018 Jul 9;4(7):e00688. doi: 10.1016/j.heliyon.2018.e00688. eCollection 2018 Jul.

Patterns of benzodiazepines use in primary care adults with anxiety disorders.

Tanguay Bernard MM1,2, Luc M1,2, Carrier JD3, Fournier L4, Duhoux A5, Côté E1,2, Lessard O1,2, Gibeault C1,2, Bocti C3,6, Roberge P1,3,7.

Author information

1

    Department of Family Medicine and Emergency Medicine, University of Sherbrooke, Canada.

2

    Family Medicine Unit of Estrie, CIUSSS de l'Estrie - CHUS, Canada.

3

    Faculty of Medicine and Health Sciences, University of Sherbrooke, Canada.

4

    CRCHUM, School of Public Health, University of Montreal, Canada.

5

    Faculty of Nursing, University of Montreal, Canada.

6

    Department of Medicine, Division of Neurology, University of Sherbrooke, Canada.

7

    CRCHUS Research Center, Canada.

Abstract

Background:  Benzodiazepines are among the most commonly prescribed drugs for anxiety disorders. While they are indicated as adjunctive treatment for short-term use according to clinical practice guidelines, previous studies have shown patterns of long-term use of benzodiazepines, which is problematic due to side effects, dependence and potential of abuse. The aims of this study were to examine among a large sample of primary care adults suffering from anxiety disorders: 1) benzodiazepine use patterns; and 2) correlates of long-term benzodiazepine use.

Methods:  Data were drawn from the "Dialogue" project, a large primary care study conducted in 64 primary care clinics in the province of Quebec, Canada. Following a mental health screening in waiting rooms, patients at risk of anxiety or depression completed the Composite International Diagnostic Interview-Simplified (CIDIS). A sample of 740 adults meeting DSM-IV criteria for Generalized Anxiety Disorder, Panic Disorder or Social Anxiety Disorder in the past 12 months took part in this study.

Results:  Benzodiazepines were used by 22.6% of participants with anxiety disorders in our primary care sample. A large majority of benzodiazepine users (88.4%) met our indicator of long-term use, as defined by utilization for more than 12 weeks including regular and as-needed use. Based on a logistic regression model, individual correlates associated with long-term benzodiazepine use included: being 30 years or older, having a comorbid physical illness, meeting criteria for comorbid agoraphobia, reporting the use of sleep-aids, and concurrent SSRI utilization.

Limitation:  Data collection with self-reported questionnaires may be subject to information bias. 

Conclusions:  Despite knowledge of the risks of long-term use of benzodiazepines, this remains a pervasive problem. Clinicians need to be mindful of patterns and risk factors leading to long-term use of benzodiazepines in patients with anxiety disorders. Results of this study should raise awareness regarding appropriate prescription practices for benzodiazepines, including decision-making in initiation, duration of prescription, and use of strategies for discontinuation in current long-term benzodiazepine users.